comparemela.com

Latest Breaking News On - Mallinckrodt pharmaceuticals - Page 4 : comparemela.com

Galectin Therapeutics Expands Clinical Team with the Appointment of Khurram Jamil, M D as Vice President, Clinical Development

NORCROSS, Ga., March 12, 2024 (GLOBE NEWSWIRE) Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target .

United statesPolf boudesChris calabreseKhurram jamilJack callicuttKevin gardnerCompany annual report on formGalectin therapeutics incKing edward medical university at lahoreOrganon pharmaceuticals united statesClinical developmentMallinckrodt pharmaceuticalsIkaria incSeaton hall universityCompany contactDrug administration

Mallinckrodt Announces Journal Publication of Real-World Data on Acthar® Gel (repository corticotropin injection) to Treat Symptomatic Sarcoidosis in African American and Non-African American Patients

/PRNewswire/ Mallinckrodt plc, a global specialty pharmaceutical company, today announced the publication of findings from a retrospective chart review of.

United statesSan franciscoNew yorkDerek belzMary mcgowanData sciencesGreen room communicationsMallinckrodt pharmaceuticalsAmerican college of chest physiciansAmerican thoracic society annual international conferenceFoundation for sarcoidosis researchAmerican medical association physician masterfileDrug administrationActhar gelAfrican americansAfrican american

Alvotech Appoints Interim Chief Quality Officer

REYKJAVIK, Iceland, Feb. 29, 2024 (GLOBE NEWSWIRE) Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manu.

New zealandYangtze riverChina generalHong kongUnited kingdomRepublic ofUnited statesSouth koreaChristina siniscalchiSandra casacaSaval latin americaRobert wessmanAlvotech holdingsTeva pharmaceuticalsKamada ltdOaktree acquisition corp

Alvotech Appoints Interim Chief Quality Officer

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that Christina Siniscalchi will join its corporate leadership team as interim Chief Quality Officer. Christina succeeds Sandra Casaca, who is leaving the company as a part of other organizational changes. Christina Siniscalchi has for over ten years served in senior quality positions for Alvogen and its manufacturing site in Norwich, NY

United kingdomNew zealandYangtze riverChina generalRepublic ofHong kongSouth koreaUnited statesSandra casacaChristina siniscalchiRobert wessmanSaval latin americaNorwich pharmaceuticalsGeorgia institute of technologyKamada ltdPharma corporation canada

Alvotech Appoints Interim Chief Quality Officer

REYKJAVIK, Iceland, Feb. 29, 2024 (GLOBE NEWSWIRE) Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that Christina Siniscalchi will join its corporate leadership team as interim Chief Quality Officer. Christina succeeds Sandra Casaca, who is leaving the company as a part of other organizational changes. Christina Siniscalchi has for over ten years served in senior quality positions

Hong kongYangtze riverChina generalNew zealandRepublic ofSouth koreaUnited statesUnited kingdomRobert wessmanSandra casacaChristina siniscalchiSaval latin americaKamada ltdTeva pharmaceuticalsPharma corporation canadaYangtze river pharmaceutical group co ltd

vimarsana © 2020. All Rights Reserved.